retinoic acid
UNASSIGNED: 3629 Background: In a phase 1B study we established that low-dose IL-2 and 13-cis retinoic acid was not toxic and could be administered safely as maintenance therapy for patients (PTS) exhibiting response or disease stabilization to chemotherapy, but at a high risk of relapse (Clin Cancer Res 7: 1251-1257, 2001).